niceritrol has been researched along with Gout in 1 studies
Niceritrol: An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions.
Gout: Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takahashi, S | 1 |
| Yamamoto, T | 1 |
| Moriwaki, Y | 1 |
| Tsutsumi, Z | 1 |
| Higashino, K | 1 |
1 other study available for niceritrol and Gout
| Article | Year |
|---|---|
Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout.
Topics: Adult; Aged; Aged, 80 and over; Apolipoproteins B; Arteriosclerosis; Cholesterol, HDL; Enzyme-Linked | 1995 |